bridging fibrosis

bridging fibrosis

A term for the presence of bands of varying thickness (the wider the bands, the more advanced the disease) of fibrous tissue and collagen seen by low-power light microscopy, which span (connect) portal spaces and/or centrilobular spaces in patients with evolving cirrhosis.
References in periodicals archive ?
No fibrosis; Fibrosis portal expansion; Bridging fibrosis; Bridging fibrosis with lobular degeneration and Cirrhosis".
3) From a pathologic perspective, Take-mura et al (7) identified granulomas, giant cells, organizing pneumonia, bridging fibrosis, lymphocytic alveolitis, lymphoid follicles, centrilobular fibrosis, and bronchiolitis as histologic features statistically more common in UIP of CrHP when compared with IPF.
Bariatric surgery in patients with nonalcoholic fatty liver disease (NAFLD) also achieved a high rate of resolution of steatosis and steatohepatitis, but it was the improvement in advanced fibrosis, including stage 3 or bridging fibrosis, that was particularly impressive.
Of these, 8 showed minimal fibrosis, 9 perisinusoidal/pericellular fibrosis (with no accompanying septal fibrosis), 15 septa formation, 15 bridging fibrosis, sometimes designated as incomplete cirrhosis or precirrhosis, and 5 cirrhosis.
The inclusion criteria were as follows: naive HCV-RNA positive patients with bridging fibrosis (METAVIR score F3) or cirrhosis (METAVIR score F4) at liver biopsy.
Further, "the treatment regimen was highly effective in patients with a historically poor treatment response, including blacks, patients with bridging fibrosis or cirrhosis, and patients with high HCV RNA levels.
The former group showed a high degree of bridging fibrosis that was absent in the latter (Fig.
MPH, from the National Cancer Institute (NCI), included 766 participants who had hepatitis C-related bridging fibrosis or cirrhosis and failed to respond to standard treatment of the anti-viral drugs peginterferon and ribavirin.
13) proposed a simple and elegant model of AST-to-platelet ratio index (APRI), which predicted bridging fibrosis as determined by the Ishak scoring system, with an AUC of 0.
Five already had fibrosis, ranging from mild to bridging fibrosis.
e mild disease, in patients with type II andtype III hepatic venous flow histopathology showed bridging fibrosis i.
Other significant predictors of sustained virologic response included lower pretreatment HCV RNA level, younger age, lower weight, higher alanine aminotransferase quotient (the patient's alanine aminotransferase level divided by the upper limit of the normal range), and the absence of bridging fibrosis or cirrhosis.